<DOC>
	<DOCNO>NCT02403635</DOCNO>
	<brief_summary>CYP3A4 involve metabolism many drug . So , important ass vivo induction effect ASP2151 enzyme determine extent possible drug interaction . The aim trial investigate potential interaction ASP2151 CYP3A4 probe substrate midazolam .</brief_summary>
	<brief_title>Drug-Drug Interaction Study : ASP2151 Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>A body mass index ( Quetelet index ) range 18.030.9 . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement , entire trial . Willingness give write consent participate reading information consent form , opportunity discuss trial investigator delegate . Willingness give write consent data enter The Overvolunteering Prevention System . Clinically relevant abnormal history , physical finding , ECG , laboratory value pretrial screening assessment could interfere objective trial safety volunteer . Any following liver function test high 1.5 time ULN screen visit : aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , ALP , bilirubin , gamma glutamyl transpeptidase ( gammaGT ) . Platelet count outside normal limit ( 129,000346,000/ÂµL ) . Presence acute chronic illness history chronic illness sufficient invalidate volunteer 's participation trial make unnecessarily hazardous . Clinically significant impaired endocrine , thyroid , hepatic , respiratory renal function , diabetes mellitus , coronary heart disease , history psychotic mental illness . Presence history sleep apnoea myasthenia gravis . History bleed diathesis . Surgery ( eg stomach bypass ) medical condition might affect absorption medicine . Presence history severe adverse reaction drug , history multiple drug allergy ( multiple define &gt; 3 ) , sensitivity trial medication . Use , 28 day first dose trial medication , prescription medicine , medicine herbal remedy ( St John 's wort ) know interfere CYP3A4 , CYP2C19 , CYP2C8 CYP2C9 metabolic pathway . Use , 7 day first dose trial medication , counter medicine , exception paracetamol ( acetaminophen ) . Participation another clinical trial new chemical entity prescription medicine within previous 3 month . Presence history drug alcohol abuse , intake 21 unit alcohol weekly 5 cigarette daily . Blood pressure heart rate seat position screen examination outside range 90140 mm Hg systolic , 4090 mm Hg diastolic ; heart rate 40_100 beats/min . However , investigator deems result clinically significant subject may include . Possibility volunteer cooperate requirement protocol . Evidence drug abuse urine testing . Positive test hepatitis B , hepatitis C , HIV1 HIV2 . Loss 400 mL blood 3 month trial , eg blood donor . Objection General Practitioner ( GP ) volunteer enter trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>HSV</keyword>
	<keyword>Herpes</keyword>
	<keyword>volunteer</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>